Baroda BNP ParibasPharmaVery High Risk

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth

Current NAV₹1418.75as of 30/5/2026

AUM4356.00 Cr

AUM

4356.00 Cr

Expense Ratio

1.95%

Min SIP

₹500

Min Lumpsum

₹1000

Launch Date

25 April 2019

Exit Load

Nil

Riskometer

LowModerateHighVery High

Risk Level: Very High

Volatility: 14.72 | Sharpe Ratio: -0.03

Fund Manager & Key Metrics

Fund ManagerSanjay Chawla(3.5 years yrs)

Volatility14.72

Sharpe Ratio-0.03

Portfolio Turnover41%

BenchmarkNifty Pharma TRI

Holdings Date25/5/2026

Asset Allocation

Equity: 96.00% | T-Bills: 4.00%

Investment Objective

Aims to provide capital appreciation by investing in Pharma securities

Top Holdings

As of 25-May-2026

1. Sun Pharmaceutical Industries Ltd.20.5%

2. Dr. Reddy's Laboratories Ltd.12.8%

3. Cipla Ltd.10.4%

4. Divi's Laboratories Ltd.9.8%

5. Torrent Pharmaceuticals Ltd.7.2%

6. Aurobindo Pharma Ltd.5.8%

7. Alkem Laboratories Ltd.5.2%

8. Lupin Ltd.4.9%

9. Ipca Laboratories Ltd.3.8%

10. Mankind Pharma Ltd.3.5%

Overview

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth overview and fund details

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ek mutual fund hai jo ki pharma sector mein invest karta hai. Iska objective hai ki long-term wealth creation ke liye best returns provide kiye ja sakein. Ye fund un investors ke liye suitable hai jo equity mutual funds mein invest karna chahte hain aur market ki volatility ko samajhte hain. Is fund ka AUM (Assets Under Management) ₹4356 crore hai, jo iska strong demand dikhata hai. Is fund ka expense ratio bhi 1.95% hai, jo ki thoda higher hai lekin industry average ke hisaab se acceptable hai.

Performance & Analysis

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth yearly return performance

Ab chaliye, Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ke yearly returns ko benchmark ke saath compare karte hain. Is fund ka 1-year return hai 5.27%, 3-year return 6.13%, aur 5-year return 5.51%. Iska benchmark Nifty Pharma TRI hai.

Period	Baroda BNP Paribas Pharma Fund - Regular Plan - Growth Returns	Nifty Pharma TRI Returns
1 Year	5.27%	Data not available
3 Year	6.13%	Data not available
5 Year	5.51%	Data not available

Performance ko dekhte hue, aap samajh sakte hain ki Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ne consistently achha perform kiya hai, lekin volatility ke kaaran returns thode fluctuate bhi hote hain. Fund ke manager Sanjay Chawla ka experience is fund ki performance par positive impact dalta hai.

⚠️ Disclaimer: Educational only. Mutual funds are subject to market risks. Past performance does not guarantee future returns. Consult your SEBI-registered advisor.

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ke top holdings aur portfolio

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ke top 5 holdings mein Sun Pharmaceutical Industries Ltd. (20.5%), Dr. Reddy's Laboratories Ltd. (12.8%), Cipla Ltd. (10.4%), Divi's Laboratories Ltd. (9.8%), aur Torrent Pharmaceuticals Ltd. (7.2%) shamil hain. Ye holdings is fund ke overall strategy ko support karti hain kyunki ye companies pharma sector ke leaders hain. Portfolio ka major focus pharma stocks par hai, jo ki ek high growth potential area hai. Yeh fund sectoral allocation par zyada concentration rakhta hai, jo ki investors ko long-term growth aur diversification ke liye ek achha platform provide karta hai.

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth risk analysis and volatility

Is fund ka riskometer "Very High" hai, jo dikhata hai ki ismein invest karna thoda riskier hai. High volatility ka matlab hai ki market fluctuations se fund ke returns mein significant changes ho sakte hain. Investors ko samajhna hoga ki yeh fund unke risk profile ke hisaab se suitable hai ya nahi. Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ka Sharpe ratio available nahi hai, lekin fund ki performance aur risk ko dekhte hue, investors ko long-term investing ke liye tayyar rahna chahiye.

Who Should Invest?

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth – aage kya? (long term outlook)

Aane wale samay mein, Baroda BNP Paribas Pharma Fund - Regular Plan - Growth ke liye kuch potential trends hain. Pharma sector historically high growth dikhata hai, especially jab health technologies aur innovations ka trend badh raha hai. Is fund ki sector exposure aur top holdings iski growth potential ko support karte hain. Lekin, aapko yaad rakhna hoga ki market ke dynamics hamesha change hote hain, aur yeh fund ka performance bhi market conditions par depend karega. Updated in May 2026, investors ko ye dekhna hoga ki kya fund apne objectives ko achieve kar raha hai.

Pros & Cons

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth – fayde aur nuksan

Pros:
- High growth potential due to pharma sector focus
- Experienced fund manager with a strong track record
- Portfolio diversification across leading pharma companies
- Long-term wealth creation opportunity
Cons:
- Very high risk and volatility
- Expense ratio of 1.95% is relatively high
- Dependence on sector performance can be risky

Frequently Asked Questions

Baroda BNP Paribas Pharma Fund - Regular Plan - Growth – aksar puche jaane wale sawaal (FAQs)

Is Baroda BNP Paribas Pharma Fund suitable for beginners?

Haan, lekin ismein invest karne se pehle aapko apne risk appetite ko samajhna zaroori hai, kyunki yeh fund very high risk category mein aata hai.

Can I invest in Baroda BNP Paribas Pharma Fund through SIP?

Haan, aap Baroda BNP Paribas Pharma Fund - Regular Plan - Growth mein SIP ke through invest kar sakte hain, jo regular investment aur disciplined approach ke liye beneficial hai.

What are the tax implications of investing in this fund?

Mutual funds par tax laga hai. Agar aap 1 saal se kam samay mein sell karte hain, to short-term capital gains tax lagega. Agar 1 saal se zyada rakha, to long-term capital gains tax applicable hai.

Returns

Period	Fund Return (%)	Benchmark (Nifty Pharma TRI) (%)
1 Year	5.27%	—
3 Years	6.13%	—
5 Years	5.51%	—
Since Launch	5.06%	—

SIP Calculator

SIP / Lumpsum Calculator

Monthly SIP Amount (₹)

SIP Period (Years)

Hold Period After SIP (Years)

Annual Step-Up (%)

Return Scenario

Based on fund's 3Y return of 6.1%

Invested: ₹956k

Gains: ₹3266k

Total Invested

₹956245.48

Total Returns

+ ₹3266423.73

Maturity Value

₹4222669.20

SIP of ₹5000 for 10 years (stepping up 10% annually), then held for 20 years at 6.1% p.a.

*Projected returns are for illustration only. Past performance does not guarantee future returns.

Similar Funds

Related Funds in Pharma

Old Bridge Mutual Fund Pharma Fund - Regular Plan - Growth Groww Mutual Fund Pharma Fund - Regular Plan - Growth Quantum Mutual Fund Pharma Fund - Regular Plan - Growth Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth Bandhan Mutual Fund Pharma Fund - Regular Plan - Growth

Compare with Alternatives

Disclaimer: Mutual fund investments are subject to market risks. Please read all scheme‑related documents carefully before investing. Past performance does not guarantee future returns. The content on this page is for educational purposes only.